Figure 7.
PhAs-LHP enhanced the inhibitory effect of gemcitabine on pancreatic cancer growth in Scid mice. Human pancreatic cancer cells, MiaPaCa-2 (5 × 106 cells) were subcutaneously injected into the flank of a Scid mouse. When tumor size reached >50 mm3, gemcitabine (Gem, 50 mg/kg), Gem plus PAO (50 μg/kg), or PhAs-LHP (200 μg/kg) was given by intraperitoneal (i.p.) injection for the time periods indicated in (A). Gem was given every 4 days. PAO and PhAs-LHP were given every other day. Tumor volume (A) and weight (B) were measured as described in the Materials and Methods section. There were 4, 4, 5, and 5 mice in the control, Gem, Gem + PAO, and Gem + PhAs-LHP groups, respectively, as indicated in (C). The mouse body weight was monitored and shown in (D). CT: control; *, p < 0.05; **, p < 0.01, compared to control; #, p < 0.05, compared to Gem alone.